Pfiz­er lines up a po­ten­tial $687M rare dis­ease buy­out to ex­pand its stake in the hot gene ther­a­py field

In the lat­est sign that the ma­jor bio­phar­ma play­ers are ea­ger­ly join­ing the big tech rush on the gene ther­a­py mar­ket, Pfiz­er has snagged an op­tion to buy a Paris-based biotech with a lead pro­gram a rare liv­er dis­ease.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.